RxDoctor Payments Data

Margery Walentuk

Psychiatric/Mental Health · Lynn, MANPI 1720488778

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.1% of the total across 270 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 14.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,674, 3.5 times the $1,054 reported in 2021. Among psychiatric/mental health clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,670in general payments, 2019–2025

Across 270 payments — averaging $24.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$958
  • Neurocrine Biosciences, Inc.$857
  • Alkermes, Inc.$676
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$549
  • Otsuka America Pharmaceutical, Inc.$484
  • E.r. Squibb & Sons, L.L.C.$480
  • plus $3K from 11 others

What the payments were for

  • Food & beverage$6,47897%
  • Education$1923%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,670 in reported general payments places this provider in the 95th percentile of 1,284 psychiatric/mental health providers in Massachusetts.

See all psychiatric/mental health providers in Massachusetts

Medicare billing

Part B allowed, 2024
$16,002
Medicare patients
54
Services billed
176

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl25$2,704
Aripiprazole25$2,473
Venlafaxine Hcl ErVenlafaxine Hcl57$1,271
Bupropion XlBupropion Hcl45$1,180
Sertraline Hcl76$793
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine24$743
Lamotrigine42$707
Trazodone Hcl39$632
Duloxetine Hcl24$587
Doxepin Hcl12$544
Olanzapine36$530
Fluoxetine Hcl23$443
Buspirone Hcl16$410
Risperidone28$354
Hydroxyzine Pamoate25$324

Paid to pharmacies, not to this prescriber.

Other psychiatric/mental health in Lynn

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →